A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate

The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.

Inclusion Criteria:

• Adult with RA for at least 6 months
• Stable weekly dosage of oral methotrexate 12.5- 25 mg/week

Exclusion Criteria:

• Severe, progressive and/or uncontrolled other disease
• Chronic or recent serious infection; current infection
• Concomitant use of RA therapy other than methotrexate with some exceptions